111 related articles for article (PubMed ID: 16145900)
1. [Androgen receptor and SMRT].
Liao GQ; Tang HH; Lü XS
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2004 Apr; 29(2):157-62. PubMed ID: 16145900
[TBL] [Abstract][Full Text] [Related]
2. The corepressors silencing mediator of retinoid and thyroid hormone receptor and nuclear receptor corepressor are involved in agonist- and antagonist-regulated transcription by androgen receptor.
Yoon HG; Wong J
Mol Endocrinol; 2006 May; 20(5):1048-60. PubMed ID: 16373395
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of MAPK-signaling pathway promotes the interaction of the corepressor SMRT with the human androgen receptor and mediates repression of prostate cancer cell growth in the presence of antiandrogens.
Eisold M; Asim M; Eskelinen H; Linke T; Baniahmad A
J Mol Endocrinol; 2009 May; 42(5):429-35. PubMed ID: 19223455
[TBL] [Abstract][Full Text] [Related]
4. The specificity of interactions between nuclear hormone receptors and corepressors is mediated by distinct amino acid sequences within the interacting domains.
Cohen RN; Brzostek S; Kim B; Chorev M; Wondisford FE; Hollenberg AN
Mol Endocrinol; 2001 Jul; 15(7):1049-61. PubMed ID: 11435607
[TBL] [Abstract][Full Text] [Related]
5. Anti-androgen effects of the pyrethroid pesticide cypermethrin on interactions of androgen receptor with corepressors.
Pan C; Wang Q; Liu YP; Xu LF; Li YF; Hu JX; Jiang M; Zhang JP; Zhang MR; Yu HM; Zhou JL; Zhou XL; Xu LC
Toxicology; 2013 Sep; 311(3):178-83. PubMed ID: 23831764
[TBL] [Abstract][Full Text] [Related]
6. Activity of androgen receptor antagonist bicalutamide in prostate cancer cells is independent of NCoR and SMRT corepressors.
Hodgson MC; Astapova I; Hollenberg AN; Balk SP
Cancer Res; 2007 Sep; 67(17):8388-95. PubMed ID: 17804755
[TBL] [Abstract][Full Text] [Related]
7. Regulation of androgen receptor activity by the nuclear receptor corepressor SMRT.
Liao G; Chen LY; Zhang A; Godavarthy A; Xia F; Ghosh JC; Li H; Chen JD
J Biol Chem; 2003 Feb; 278(7):5052-61. PubMed ID: 12441355
[TBL] [Abstract][Full Text] [Related]
8. Agonist-antagonist induced coactivator and corepressor interplay on the human androgen receptor.
Dotzlaw H; Papaioannou M; Moehren U; Claessens F; Baniahmad A
Mol Cell Endocrinol; 2003 Dec; 213(1):79-85. PubMed ID: 15062576
[TBL] [Abstract][Full Text] [Related]
9. The BCL-6 POZ domain and other POZ domains interact with the co-repressors N-CoR and SMRT.
Huynh KD; Bardwell VJ
Oncogene; 1998 Nov; 17(19):2473-84. PubMed ID: 9824158
[TBL] [Abstract][Full Text] [Related]
10. Structural basis for nuclear receptor corepressor recruitment by antagonist-liganded androgen receptor.
Hodgson MC; Shen HC; Hollenberg AN; Balk SP
Mol Cancer Ther; 2008 Oct; 7(10):3187-94. PubMed ID: 18852122
[TBL] [Abstract][Full Text] [Related]
11. Formation of AR-SMRT binding in prostate cancer cells treated with natural histone deacetylase inhibitor.
Trtková K; Pašková L; Matiješčuková N; Kolář Z
Cancer Biomark; 2010; 7(2):79-90. PubMed ID: 21178266
[TBL] [Abstract][Full Text] [Related]
12. The functional relationship between co-repressor N-CoR and SMRT in mediating transcriptional repression by thyroid hormone receptor alpha.
Choi KC; Oh SY; Kang HB; Lee YH; Haam S; Kim HI; Kim K; Ahn YH; Kim KS; Yoon HG
Biochem J; 2008 Apr; 411(1):19-26. PubMed ID: 18052923
[TBL] [Abstract][Full Text] [Related]
13. Neuroanatomical distribution and colocalisation of nuclear receptor corepressor (N-CoR) and silencing mediator of retinoid and thyroid receptors (SMRT) in rat brain.
van der Laan S; Lachize SB; Schouten TG; Vreugdenhil E; de Kloet ER; Meijer OC
Brain Res; 2005 Oct; 1059(2):113-21. PubMed ID: 16212947
[TBL] [Abstract][Full Text] [Related]
14. A novel mutation F826L in the human androgen receptor in partial androgen insensitivity syndrome; increased NH2-/COOH-terminal domain interaction and TIF2 co-activation.
Wong HY; Hoogerbrugge JW; Pang KL; van Leeuwen M; van Royen ME; Molier M; Berrevoets CA; Dooijes D; Dubbink HJ; van de Wijngaart DJ; Wolffenbuttel KP; Trapman J; Kleijer WJ; Drop SL; Grootegoed JA; Brinkmann AO
Mol Cell Endocrinol; 2008 Sep; 292(1-2):69-78. PubMed ID: 18656523
[TBL] [Abstract][Full Text] [Related]
15. Very strong correlation between dominant negative activities of mutant thyroid hormone receptors and their binding avidity for corepressor SMRT.
Matsushita A; Misawa H; Andoh S; Natsume H; Nishiyama K; Sasaki S; Nakamura H
J Endocrinol; 2000 Dec; 167(3):493-503. PubMed ID: 11115777
[TBL] [Abstract][Full Text] [Related]
16. Subtype specific effects of peroxisome proliferator-activated receptor ligands on corepressor affinity.
Stanley TB; Leesnitzer LM; Montana VG; Galardi CM; Lambert MH; Holt JA; Xu HE; Moore LB; Blanchard SG; Stimmel JB
Biochemistry; 2003 Aug; 42(31):9278-87. PubMed ID: 12899614
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of the dihydrotestosterone-activated androgen receptor by nuclear receptor corepressor.
Cheng S; Brzostek S; Lee SR; Hollenberg AN; Balk SP
Mol Endocrinol; 2002 Jul; 16(7):1492-501. PubMed ID: 12089345
[TBL] [Abstract][Full Text] [Related]
18. Functional in vivo interaction between the amino-terminal, transactivation domain and the ligand binding domain of the androgen receptor.
Doesburg P; Kuil CW; Berrevoets CA; Steketee K; Faber PW; Mulder E; Brinkmann AO; Trapman J
Biochemistry; 1997 Feb; 36(5):1052-64. PubMed ID: 9033395
[TBL] [Abstract][Full Text] [Related]
19. Corepressor SMRT specifically represses the transcriptional activity of orphan nuclear receptor hB1F/hLRH-1.
Xu PL; Kong YY; Xie YH; Wang Y
Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai); 2003 Oct; 35(10):897-903. PubMed ID: 14515206
[TBL] [Abstract][Full Text] [Related]
20. Androgen receptor ligand-binding domain interaction and nuclear receptor specificity of FXXLF and LXXLL motifs as determined by L/F swapping.
Dubbink HJ; Hersmus R; Pike AC; Molier M; Brinkmann AO; Jenster G; Trapman J
Mol Endocrinol; 2006 Aug; 20(8):1742-55. PubMed ID: 16627595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
